Significant progress has been made over the past year to improve, extend and save the lives of cancer patients, according to the 12th annual report Cancer Progression Report issued by the American Association for Cancer Research (AACR).
Researchers from AACR present the latest impactful advances cancer patientshighlighting progress from 1 August 2021 to 31 July 2022 and focusing on cancer diseasemortality and survival statistics and recent research.
As of January 1, 2022, the number of cancer survivors in the United States will reach more than 18 million, according to the report. The overall age-adjusted cancer death rate has declined steadily since the 1990s, decreasing by 2.3 percent annually From 2016 to 2019, the US Food and Drug Administration approved eight new cancer drugs in the clinical cancer treatment continuum, including number one drug for treatment uveal melanoma and the first molecularly targeted therapeutic for von Hippel-Lindau syndrome. In addition, the use of 10 anticancer therapeutics was expanded and two new diagnostic imaging tools were approved. Several AI-based tools have been developed to improve cancer detection and diagnosis.
“Targeted therapies, immunotherapy, and other new therapeutic approaches in clinical practice all stem from fundamental discoveries in basic science,” said Lisa M. Cousens, Ph.D., AACR President. “Investment in cancer science and support scientific education at all levels, absolutely necessary to drive the next wave of discovery and accelerate progress.”
AACR Cancer Progress Report 2022
Copyright © 2022 Health Day. All rights reserved.
Citation: AACR Issues 12th Annual Cancer Progress Report (2022, September 21) Retrieved September 21, 2022, from https://medicalxpress.com/news/2022-09-aacr-issues-12th-annual-cancer .html
This document is subject to copyright. Except in good faith for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.